创新药研究框架之GLP-1：内卷时代，更看好小分子、多靶点、长效三大方向差异化突破

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical sector, indicating a positive outlook compared to the market [2]. Core Insights - The report emphasizes three key directions for the future development of GLP-1 drugs: small molecules, multi-target therapies, and long-acting formulations, which are expected to provide differentiated breakthroughs in a competitive environment [1][13]. - The global market for GLP-1 drugs is rapidly expanding, with an estimated sales scale exceeding $36.6 billion in 2023, driven by the growth in diabetes and weight loss markets [9][11]. Summary by Sections 1. GLP-1 Overview - The report highlights the promising growth of GLP-1 drugs, focusing on small molecules, multi-target therapies, and long-acting formulations as key areas for differentiation [1][13]. 2. Small Molecule GLP-1 - Domestic companies are primarily following Pfizer's Danuglipron route, with several products entering Phase 2 clinical trials [17]. - The advantages of small molecule GLP-1 drugs include oral administration, which enhances convenience and reduces production costs compared to traditional peptide drugs [15][16]. - Early clinical data for Orforglipron shows superior weight loss efficacy compared to Danuglipron, indicating potential for future developments [29][33]. 3. Multi-Target GLP-1 - Multi-target GLP-1 drugs are expected to demonstrate superior efficacy compared to single-target products, with several candidates in various stages of clinical trials [35][36]. - The report notes that the dual-target product Mazdutide from Innovent is in the NDA stage, while other multi-target products are in Phase 2 and Phase 3 trials [36][37]. 4. Long-Acting GLP-1 - Long-acting GLP-1 formulations are anticipated to improve patient adherence, with several products currently in Phase 2 clinical trials [45][46]. - The report discusses the potential for longer dosing intervals (bi-weekly or monthly) to enhance patient compliance compared to weekly injections [43][47]. 5. GLP-1 Upstream Supply Chain - The demand for GLP-1 drugs is substantial, with significant investment value in the upstream peptide supply chain due to the rapid expansion of the market [50]. - The report estimates minimum raw material requirements for GLP-1 drugs in weight loss, diabetes, and potential NASH applications, highlighting the growing need for upstream suppliers [51]. 6. Recommended Stocks - The report suggests focusing on several companies in the drug formulation space, including Innovent, Hengrui, and East China Pharmaceutical, as well as upstream suppliers like Hanyu Pharmaceutical and Nuotai Biological [53][76].